The French company is a pre-clinical biotech company with a strong expertise in the fild of monogenetic disorders designing and developing miniaturised and automated in vitro cellular and phenotypic assays based on the use of patient cells. It is developing its first drug-candidate in the field of inborn skin diseases.
The company is already working closely with several patient organisations in the following areas of expertise: screening molecules, drug repurposing, inherited metabolic disorders, genodermatoses and inborn neurodevelopmental disorders.
It has research laboratories with facilities for cell culture, cellular biology, molecular biology, biochemistry and chemistry. It is based into a very fruitful environment with excellent healthcare science.
The process implemented by the company is the following:
- it collects biopsies from patients with a well-established monogenetic disorder in order to isolate fibroblasts and keratinocytes that are amplified and biobanked through its own database.
- assays are then developed using these primary or immortalized attaching cells in a standard format 384-well plates.
- the company uses imaging, spectrometry and mass spectrometry to follow the most clinically-relevant phenotypes of the diseased cells for screening molecules.
The technology can be easily settled for using other types of attaching cells. The development of a miniaturized 2D reconstituted skin suitable for high throughput screening is on-going.
The company has assembled its own and proprietary collection of molecules approved for human use that is suitable for drug repurposing. The collection contains Active Pharmaceutical Ingredients (APIs), excipients, Generally Recognized As Safe (GRAS), food supplements and phase one metabolites of APIs.
It is looking to enhance collaborations with patient associations, as well as academic organisations and private companies on drug discovery projects for molecule screening on patient primary cells and drug repurposing, offering research or technical cooperation agreements.